MedTrace Logo

Ovarian Stimulation Single Injection Elonva

NCT02414737 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-06-21

No results posted yet for this study

Summary

We would like to propose that it may be possible to use a solitary dose of Elonva (corifollitrophin alpha) as the sole gonadotrophin (FSH) stimulant for the vast majority of women undergoing IVF, assuming that it is possible that "coasting" (withholding short acting rFSH) from day 8 of the stimulation until trigger/ oocyte retrieval will still result in a significant number of mature oocytes being produced and an acceptable pregnancy rate.

Conditions

Interventions

DRUG

corifollitrophin alfa

use of a single dose of corifollitrophin alfa to provide adequate controlled ovarian hyperstimulation during IVF treatment

Sponsors & Collaborators

  • Flinders University

    collaborator OTHER

  • Flinders Fertility

    lead INDUSTRY

Principal Investigators

  • Kelton Tremellen, MD PhD · Flinders University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
37 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02414737 on ClinicalTrials.gov